tesidolumab

Tesidolumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that targets complement component C5. By binding to C5, tesidolumab inhibits its cleavage and prevents the formation of the membrane attack complex, thereby blocking terminal complement pathway activation. This mechanism provides immunomodulatory effects and has potential therapeutic applications in diseases mediated by complement activation. Tesidolumab binds to a distinct epitope on C5 compared to other anti-C5 antibodies such as eculizumab, allowing it to inhibit both variant and non-variant forms of C5[1][3][4][5]. The drug was originally developed by MorphoSys and Novartis for indications including paroxysmal nocturnal haemoglobinuria (PNH), uveitis, age-related macular degeneration, choroiditis, thrombotic microangiopathy, among others[2][4].

Other names

NOV-4NOV4NOV 4